Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890999 | 0.86 | CYP4F2 (0.35) | CYP4F2CYP4A11GAACNR2MEN1 | |
| SCHEMBL9891008 | 0.83 | GNAI3 (0.36) | CYP4F2CYP4A11MEN1KMT2ATHRB | |
| SCHEMBL9891004 | 0.77 | GAA (0.39) | GAAMEN1KMT2ATHRBHTT | |
| SCHEMBL9891006 | 0.76 | HPGD (0.44) | GAAMEN1KMT2APKM | |
| SCHEMBL9890998 | 0.73 | EPHX1 (0.39) | — | |
| SCHEMBL17617167 | 0.73 | CYP4F2 (0.44) | CYP4F2CYP4A11GAAMEN1KMT2A | |
| SCHEMBL17617205 | 0.73 | CYP4F2 (0.44) | CYP4F2CYP4A11GAAMEN1KMT2A | |
| SCHEMBL8716223 | 0.72 | SMYD3 (0.55) | SMYD3GAAMEN1KMT2A | |
| SCHEMBL8716219 | 0.72 | SMYD3 (0.55) | SMYD3GAAMEN1KMT2A | |
| SCHEMBL6383219 | 0.72 | ALDH1A1 (0.46) | CYP4F2CYP4A11GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | APOSENSE LTD. (IL) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142722-A1 | CONJUGATES OF CYTOTOXIC DRUGS | CD47, MCL1, BAD | SMYD3 2110/4885CYP4F2 2276/4885CYP4A11 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.